乌鸦传媒

<乌鸦传媒 class='mpt-top_cat_title'>Meeting Coverage >

ASHP

<乌鸦传媒>Cost Savings With Pharmacist-Driven Substitutions of Oncology Biosimilars

Regional clinical pharmacists helped community oncology practices navigate logistics, financials

<乌鸦传媒>Drug-Diversion Program Cut Controlled-Substance Discrepancies at Mount Sinai

A daily audit of EHR and dispensing machines revealed documentation mistakes, other errors

<乌鸦传媒>Research on the Effects of Posture on Drug Absorption Lacking

Major gaps in methodology revealed in studies evaluating posture and pharmacokinetics

<乌鸦传媒>Beware Flu and COVID Vax Mix-Ups and Other Medication Errors

Medication safety group previews new best practices for next year

<乌鸦传媒>Digital HTN, Diabetes Monitoring Program a Boon for Patients

Program reports growth and better outcomes

<乌鸦传媒>U.S. Dragging Its Feet on Biosimilar Approvals, Pharmacist Says

Introduction of biosimilars falling behind that of other countries

<乌鸦传媒>The ASHP Wants to Stop White Bagging on Prescription Drugs

This practice "jeopardizes patient care," says ASHP official

<乌鸦传媒>Hospitals Confront New Accreditation Standards to Come

Small, rural sites may be uniquely affected by Joint Commission standards expected in 2022

<乌鸦传媒>Efforts Needed to De-Escalate Use of Inhaled Corticosteroids in COPD

Clinicians are not always following the guidelines

<乌鸦传媒>C. Difficile Inpatient Stays Long, Costly

LAS VEGAS -- Among the many factors that contribute to the burgeoning costs associated with Clostridium difficile infections are long hospital stays, particularly in intensive care units, and the need for multiple specialist consultations, a chart review determined.

<乌鸦传媒>Melanoma Tx Ups Survival, but Very Pricey

LAS VEGAS -- The oral BRAF inhibitor vemurafenib (Zelboraf) increased survival in patients with metastatic melanoma, but the cost may not justify its use in a state Medicaid program, an analysis suggested.

<乌鸦传媒>ALS Drug Gets Review for VA Coverage

LAS VEGAS -- Riluzole (Rilutek) should remain on the Veterans Administration formulary as a treatment for patients with amyotrophic lateral sclerosis, despite having only modest benefits and considerable cost, a researcher said here.

<乌鸦传媒>Enbrel Best Buy Among Anti-TNFs

LAS VEGAS -- The tumor necrosis factor inhibitor etanercept (Enbrel) was more cost-effective for the treatment of rheumatoid arthritis than were two other biologic agents in this class, a budget impact analysis found.